Filtered By:
Condition: Diabetes
Nutrition: Weight Loss

This page shows you your search results in order of relevance. This is page number 15.

Order by Relevance | Date

Total 290 results found since Jan 2013.

Development of a Mobile Application Platform for Self-Management of Obesity Using Artificial Intelligence Techniques
Int J Telemed Appl. 2021 Aug 27;2021:6624057. doi: 10.1155/2021/6624057. eCollection 2021.ABSTRACTObesity is a major global health challenge and a risk factor for the leading causes of death, including heart disease, stroke, diabetes, and several types of cancer. Attempts to manage and regulate obesity have led to the implementation of various dietary regulatory initiatives to provide information on the calorie contents of meals. Although knowledge of the calorie content is useful for meal planning, it is not sufficient as other factors, including health status (diabetes, hypertension, etc.) and level of physical activity,...
Source: International Journal of Telemedicine and Applications - September 6, 2021 Category: Information Technology Authors: Sylvester M Sefa-Yeboah Kwabena Osei Annor Valencia J Koomson Firibu K Saalia Matilda Steiner-Asiedu Godfrey A Mills Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

wEight chanGes, caRdio-mEtabolic risks and morTality in patients with hyperthyroidism (EGRET): a protocol for a CPRD-HES linked cohort study
Introduction Hyperthyroidism is a common condition affecting up to 3% of the UK population. Treatment improves symptoms and reduces the risk of atrial fibrillation and stroke that contribute to increased mortality. The most common symptom is weight loss, which is reversed during treatment. However, the weight regain may be excessive, contributing to increased risk of obesity. Current treatment options include antithyroid drugs, radioiodine and thyroidectomy. Whether there are differences in either weight change or the long-term cardiometabolic risk between the three treatments is unclear. Methods and analysis The study wi...
Source: BMJ Open - October 1, 2021 Category: General Medicine Authors: Torlinska, B., Hazlehurst, J. M., Nirantharakumar, K., Thomas, G. N., Priestley, J. R., Finnikin, S. J., Saunders, P., Abrams, K. R., Boelaert, K. Tags: Open access, Diabetes and Endocrinology Source Type: research

Why You Shouldn ’t Exercise to Lose Weight
Many of us are lacing up our sneakers and starting (or restarting) exercise regimens in hopes of shedding unwanted pounds. Unquestionably, aiming to be more active is a good thing. But if the main reason is to lose weight, your New Year’s resolution could very well backfire. For starters, exercise—at least the kind most of us do—is typically ineffective for weight loss. Take walking, for example. A 150-pound person who walks briskly for 30 minutes will burn, on average, around 140 calories. That’s equal to one can of soda—not exactly a great return on your investment of time and effort. It&rsq...
Source: TIME: Health - January 12, 2022 Category: Consumer Health News Authors: Robert J. Davis Tags: Uncategorized Source Type: news

Effects of exercise mode on improving cardiovascular function and cardiorespiratory fitness after bariatric surgery: A narrative review
Am J Phys Med Rehabil. 2022 Jan 14. doi: 10.1097/PHM.0000000000001946. Online ahead of print.ABSTRACTObesity affects 600 million people globally and increases the risk of developing cardiovascular disease, stroke, diabetes, and cancer. Bariatric surgery is an increasingly popular therapeutic intervention for morbid obesity to induce rapid weight loss and reduce obesity-related comorbidities. However, some bariatric surgery patients, following what is considered a successful surgical procedure, continue to manifest obesity-related health issues, including weight gain, reduced physical function, persistent elevations in bloo...
Source: Health Physics - January 16, 2022 Category: Physics Authors: Abeer M Mahmoud Andr éa Lúcia Gonçalves da Silva Larissa Delgado Andr é Chueh-Lung Hwang Richard Severin Lisa Sanchez-Johnsen Audrey Borghi-Silva Ahmed Elokda Ross Arena Shane A Phillips Source Type: research

The effect of obesity, hypertension, diabetes mellitus, alcohol, and sleep apnea on the risk of atrial fibrillation
Physiol Res. 2021 Dec 30;70(Suppl4):S511-S525.ABSTRACTAtrial fibrillation (AF) is the most common sustained cardiac arrhythmia associated with a two-fold increase in mortality caused by a higher risk of stroke and heart failure. Currently, AF is present in ~ 2 % of the general population, and its incidence and prevalence are increasing. Obesity, hypertension, diabetes mellitus, obstructive sleep apnea, and alcohol consumption increase the risk of AF. Each unit of increase in BMI increases the risk of AF by 3 %, and intensive weight loss is also associated with reduced AF recurrence. Hypertension increases the risk of AF by...
Source: Physiological Research - February 24, 2022 Category: Physiology Authors: Z Čarná P Osman čík Source Type: research